Literature DB >> 7565543

1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.

.   

Abstract

Pneumocystis carinii pneumonia (PCP) is the most common opportunistic infection in children who have acquired immunodeficiency syndrome (AIDS). Despite the publication of guidelines for prophylaxis against PCP for children infected with human immunodeficiency virus (HIV) in 1991 (1), ongoing AIDS surveillance has detected no substantial decrease in PCP incidence among HIV-infected infants. Studies indicate that this continued incidence is associated with failure to identify HIV-infected children before PCP occurs and with limitations in the ability of CD4+ measurements to identify children at risk for PCP. In March 1994, the National Pediatric & Family HIV Resource Center, in collaboration with CDC, convened a working group to review additional data about the occurrence of PCP among HIV-infected children and to reevaluate the 1991 PCP prophylaxis guidelines for children. This report summarizes these new data and presents revised PCP prevention guidelines that recommend a) promptly identifying children born to HIV-infected women and initiating regular diagnostic and immunologic monitoring of such children; b) beginning PCP prophylaxis at 4-6 weeks of age for all children who have been perinatally exposed to HIV; c) continuing prophylaxis through 12 months of age for HIV-infected children; and d) making decisions regarding prophylaxis for HIV-infected children > or = 12 months of age based on CD4+ measurements and whether PCP previously has occurred.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7565543

Source DB:  PubMed          Journal:  MMWR Recomm Rep        ISSN: 1057-5987


  9 in total

1.  Alveolar macrophages in neonatal mice are inherently unresponsive to Pneumocystis murina infection.

Authors:  Cathryn Kurkjian; Melissa Hollifield; J Louise Lines; Amy Rogosky; Kerry M Empey; Mahboob Qureshi; Stephen A Brown; Beth A Garvy
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Care of the infant born to an HIV-positive mother.

Authors: 
Journal:  Paediatr Child Health       Date:  2000-04       Impact factor: 2.253

3.  Prophylaxis of Pneumocystis carinii pneumonia in HIV-infected children one to five years old: a multicenter surveillance study in paediatric hospitals in Germany.

Authors:  N Rümmelein; U Wintergerst; B H Belohradsky
Journal:  Infection       Date:  1998 Mar-Apr       Impact factor: 3.553

4.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

5.  Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Authors:  M Mirochnick; E Cooper; K McIntosh; J Xu; J Lindsey; D Jacobus; L Mofenson; J L Sullivan; W Dankner; L M Frenkel; S Nachman; D W Wara; D Johnson; V R Bonagura; M H Rathore; C K Cunningham; J McNamara
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

6.  Maturational changes in peripheral lymphocyte subsets pertinent to monitoring human immunodeficiency virus-infected Chinese pediatric patients.

Authors:  K M Kam; W L Leung; K H Wong; S S Lee; M Y Hung; M Y Kwok
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

7.  Nine-year follow-up of HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.

Authors:  Richard S B Wanless; Sorin Rugină; Simona Maria Ruţă; Irina-Magdalena Dumitru; Roxana Carmen Cernat; Heidi L Schwarzwald; Nancy R Calles; Gordon E Schutze; Ana-Maria Schweitzer; Heather R Draper; Mark W Kline
Journal:  Germs       Date:  2013-09-01

8.  Treatment and disease progression in a birth cohort of vertically HIV-1 infected children in Ukraine.

Authors:  Saboura Mahdavi; Ruslan Malyuta; Igor Semenenko; Tatyana Pilipenko; Claire Thorne
Journal:  BMC Pediatr       Date:  2010-11-23       Impact factor: 2.125

9.  Management of opportunistic infections in pediatric HIV.

Authors:  R H Merchant; Zafar A Quadir
Journal:  Indian J Pediatr       Date:  2002-11       Impact factor: 5.319

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.